Paediatric indication for Xolair

1 October 2009

The licence for Xolair (omalizumab), which is indicated for add-on therapy in severe persistent allergic IgE-mediated asthma, has been extended to include children as young as six years.

View Xolair drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Close-up image of a COVID-19 antibody

Suspending methotrexate therapy shown to improve COVID booster response

Findings from a recent study showed that a two-week...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...